



**TOSHKENT TIBBIYOT AKADEMIYASI URGANCH FILIALI**  
**JANUBIY OROLBO‘YI TIBBIYOT JURNALI**  
**2 - TOM, MAXSUS SON-2. 2026**  
**14.00.00 - TIBBIYOT FANLARI ISSN: 3093-8740**

**UDK: 616.12-008.46-085**

**MODERN TREATMENT METHODS OF HEART FAILURE**



**Umurqulov Husniddin**

Central Asian Medical University, Assistant of the Department of Physiology and Pharmacology

[husniddinscience@gmail.com](mailto:husniddinscience@gmail.com)

<https://orcid.org/0009-0001-6894-7204>

**Abstract:** Heart failure is one of the leading causes of morbidity and mortality worldwide and remains a major challenge for modern healthcare systems. The increasing prevalence of cardiovascular diseases, population aging, hypertension, diabetes mellitus, and obesity has contributed to the growing burden of heart failure. Recent advances in cardiovascular medicine have led to the development of innovative treatment strategies that significantly improve patient outcomes. This article examines contemporary approaches to heart failure management, including pharmacological therapy, device-based interventions, and advanced treatment options for severe cases. Particular attention is given to angiotensin receptor-neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, sodium-glucose cotransporter-2 inhibitors, implantable cardiac devices, mechanical circulatory support systems, and heart transplantation. The article also discusses future perspectives in heart failure treatment, including personalized medicine, artificial intelligence, gene therapy, and regenerative medicine. The findings indicate that modern multidisciplinary approaches contribute to improved survival, reduced hospitalization rates, and enhanced quality of life among patients with heart failure.

**Keywords:** Heart failure, cardiovascular disease, pharmacological therapy, cardiac resynchronization therapy, implantable cardioverter-defibrillator, heart transplantation, personalized medicine.

**СОВРЕМЕННЫЕ МЕТОДЫ ЛЕЧЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ**

**Хусниддин Умуркулов**

Ассистент кафедры физиологии и Центрально-Азиатский медицинский университет

[husniddinscience@gmail.com](mailto:husniddinscience@gmail.com)

<https://orcid.org/0009-0001-6894-7204>

**Аннотация:** Сердечная недостаточность является одной из основных причин заболеваемости и смертности во всем мире и остается серьезной проблемой современной системы здравоохранения. Рост распространенности сердечно-сосудистых заболеваний, старение населения, артериальная гипертензия, сахарный диабет и ожирение способствуют увеличению числа пациентов с сердечной недостаточностью. Последние достижения в области кардиологии привели к разработке инновационных методов лечения, значительно улучшающих результаты терапии. В данной статье рассматриваются современные подходы к лечению сердечной недостаточности, включая медикаментозную терапию, использование



**TOSHKENT TIBBIYOT AKADEMIYASI URGANCH FILIALI**  
**JANUBIY OROLBO‘YI TIBBIYOT JURNALI**  
**2 - TOM, MAXSUS SON-2. 2026**  
**14.00.00 - TIBBIYOT FANLARI ISSN: 3093-8740**

имплантируемых устройств и передовые методы лечения тяжелых форм заболевания. Особое внимание уделено ингибиторам рецепторов ангиотензина и неприлизина, бета-блокаторам, антагонистам минералокортикоидных рецепторов, ингибиторам натрий-глюкозного котранспортера 2 типа, кардиологическим устройствам и трансплантации сердца. Результаты показывают, что современные междисциплинарные подходы способствуют повышению выживаемости, снижению частоты госпитализаций и улучшению качества жизни пациентов.

**Ключевые слова:** Сердечная недостаточность, сердечно-сосудистые заболевания, медикаментозная терапия, кардиоресинхронизирующая терапия, имплантируемый кардиовертер-дефибриллятор, трансплантация сердца, персонализированная медицина.

**YURAK YETISHMOVCHILIGINI ZAMONAVIY DAVOLASH USULLARI**

**Husniddin Umurqulov**

Central Asian Medical University, Fiziologiya va Farmakologiya kafedrası assistenti

husniddinscience@gmail.com

<https://orcid.org/0009-0001-6894-7204>

**Annotatsiya:** Yurak yetishmovchiligi dunyo miqyosida kasallanish va o‘limning asosiy sabablaridan biri bo‘lib, zamonaviy sog‘liqni saqlash tizimi oldidagi dolzarb muammolardan hisoblanadi. Yurak-qon tomir kasalliklari, aholi qarishi, arterial gipertenziya, qandli diabet va semizlikning keng tarqalishi yurak yetishmovchiligi bilan kasallanish ko‘rsatkichlarining ortishiga olib kelmoqda. Kardiologiya sohasidagi so‘nggi yutuqlar ushbu kasallikni davolashning samarali va innovatsion usullarini ishlab chiqishga imkon yaratdi. Mazkur maqolada yurak yetishmovchiligini davolashning zamonaviy yondashuvlari, jumladan farmakologik terapiya, qurilmaviy davolash usullari hamda og‘ir holatlarda qo‘llaniladigan ilg‘or davolash texnologiyalari tahlil qilingan. Angiotenzin retseptorlari-neprilizin ingibitorlari, beta-blokatorlar, mineralokortikoid retseptorlari antagonistlari, natriy-glyukoza kotransporteri-2 ingibitorlari, implantatsiya qilinadigan yurak qurilmalari va yurak transplantatsiyasining klinik ahamiyati yoritilgan. Tadqiqot natijalari zamonaviy kompleks yondashuvlar bemorlarning yashovchanligini oshirish, shifoxonaga yotqizilish holatlarini kamaytirish va hayot sifatini yaxshilashga xizmat qilishini ko‘rsatadi.

**Kalit so‘zlar:** yurak yetishmovchiligi, yurak-qon tomir kasalliklari, farmakologik terapiya, kardial resinxronizatsiya terapiyasi, implantatsiya qilinadigan kardioverter-defibrillyator, yurak transplantatsiyasi, shaxsiylashtirilgan tibbiyot.

**Introduction**

Heart failure is one of the most significant challenges in modern cardiology, affecting millions of people worldwide and contributing substantially to morbidity, mortality, and healthcare expenditures. It is a complex clinical syndrome that occurs when the heart is unable to pump sufficient blood to meet the metabolic demands of the body or can do so only at the expense of elevated cardiac filling pressures. Patients with heart failure commonly experience symptoms such as dyspnea, fatigue, reduced exercise tolerance, and peripheral edema, which significantly impair their quality of life. The growing prevalence of cardiovascular risk factors, including hypertension, coronary artery disease, diabetes mellitus, obesity, and population aging, has led to a continuous increase in the incidence and prevalence of heart failure globally. Over the past decades, considerable progress has been made in understanding the pathophysiological mechanisms underlying heart failure. Advances in molecular biology, cardiovascular imaging, and clinical research have provided valuable insights into the neurohormonal, inflammatory, and metabolic pathways involved in disease progression. These discoveries have contributed to the development of innovative therapeutic strategies aimed not only at symptom relief but also at improving long-term clinical outcomes and survival. As a result, the



**TOSHKENT TIBBIYOT AKADEMIYASI URGANCH FILIALI**  
**JANUBIY OROLBO‘YI TIBBIYOT JURNALI**  
**2 - TOM, MAXSUS SON-2. 2026**  
**14.00.00 - TIBBIYOT FANLARI ISSN: 3093-8740**

management of heart failure has evolved from a predominantly symptomatic approach to a comprehensive, evidence-based treatment paradigm.

Modern treatment of heart failure includes a combination of pharmacological and non-pharmacological interventions. Contemporary drug therapies, such as angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter-2 inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and other guideline-directed medical therapies, have demonstrated significant benefits in reducing hospitalization rates and cardiovascular mortality. In addition, technological advancements have enabled the widespread use of implantable cardioverter-defibrillators, cardiac resynchronization therapy devices, mechanical circulatory support systems, and heart transplantation for selected patients with advanced disease. The concept of personalized medicine has also become increasingly important in heart failure management. Treatment decisions are now based on individual patient characteristics, disease etiology, ejection fraction status, comorbid conditions, and risk stratification. This patient-centered approach enhances therapeutic effectiveness and contributes to improved quality of life and clinical outcomes. Furthermore, ongoing clinical trials continue to explore novel therapeutic targets and emerging technologies that may further transform the management of heart failure in the future.

#### **Relevance**

Heart failure remains one of the leading causes of hospitalization, disability, and mortality worldwide, representing a major public health challenge. The increasing prevalence of cardiovascular diseases, population aging, sedentary lifestyles, obesity, hypertension, and diabetes mellitus has significantly contributed to the growing burden of heart failure. Despite substantial progress in diagnosis and treatment, the disease continues to be associated with high morbidity and mortality rates, resulting in considerable social and economic consequences. According to recent international studies, millions of individuals are currently living with heart failure, and its prevalence is expected to rise further in the coming decades. Therefore, the investigation of modern treatment approaches and the evaluation of their clinical effectiveness are highly relevant for improving patient outcomes and reducing healthcare costs.

#### **Aim**

The aim of this article is to analyze contemporary treatment methods for heart failure and evaluate their effectiveness in improving clinical outcomes, reducing hospitalization rates, and enhancing the quality of life of patients. The study also aims to examine recent advances in pharmacological therapy, device-based interventions, and innovative treatment strategies that contribute to the management of heart failure.

#### **Main part**

Heart failure is one of the most common and serious cardiovascular disorders worldwide. It represents a major public health concern because of its increasing prevalence and high mortality rates. The condition occurs when the heart is unable to pump blood efficiently to satisfy the metabolic demands of the body. As a result, patients often experience symptoms such as fatigue, dyspnea, reduced physical capacity, and fluid retention. The prevalence of heart failure has increased significantly due to population aging and the growing incidence of hypertension, diabetes mellitus, obesity, and coronary artery disease. Despite substantial improvements in cardiovascular medicine, heart failure remains a leading cause of hospitalization among adults and elderly individuals. The disease negatively affects patients' quality of life and imposes a considerable economic burden on healthcare systems. Advances in diagnostic technologies have improved the early detection and classification of heart failure. At the same time, modern therapeutic approaches have enhanced survival rates and reduced disease-related complications. However, many patients continue to experience recurrent hospital admissions and progressive deterioration of cardiac function. Therefore, continuous research is required to identify more effective treatment strategies. The growing burden of heart failure highlights the importance of evidence-based management and multidisciplinary care.



**TOSHKENT TIBBIYOT AKADEMIYASI URGANCH FILIALI**  
**JANUBIY OROLBO‘YI TIBBIYOT JURNALI**  
**2 - TOM, MAXSUS SON-2. 2026**  
**14.00.00 - TIBBIYOT FANLARI ISSN: 3093-8740**

Understanding current challenges in heart failure treatment is essential for improving clinical outcomes and reducing mortality.

Heart failure develops as a result of structural or functional abnormalities that impair the heart's ability to maintain adequate circulation. Various cardiovascular diseases can contribute to its development, including ischemic heart disease, hypertension, cardiomyopathy, and valvular disorders. When cardiac output decreases, several compensatory mechanisms become activated to preserve organ perfusion. These mechanisms include stimulation of the sympathetic nervous system and activation of the renin-angiotensin-aldosterone system. Although initially beneficial, prolonged activation of these pathways contributes to myocardial remodeling and worsening cardiac dysfunction. Heart failure is commonly classified according to left ventricular ejection fraction into reduced, mildly reduced, and preserved ejection fraction categories. Clinical manifestations vary depending on disease severity and underlying etiology. The most common symptoms include shortness of breath, fatigue, exercise intolerance, and peripheral edema. Patients may also experience orthopnea, paroxysmal nocturnal dyspnea, and fluid accumulation in various tissues. Physical examination often reveals pulmonary congestion, elevated jugular venous pressure, and lower extremity swelling. Accurate diagnosis requires a combination of clinical assessment, laboratory investigations, electrocardiography, and echocardiography. Biomarkers such as natriuretic peptides are valuable tools for diagnosis and prognosis.

Pharmacological therapy is the foundation of modern heart failure management and aims to improve survival, reduce symptoms, and prevent disease progression. Current clinical guidelines recommend the use of several evidence-based medications that target key pathophysiological pathways involved in heart failure. Angiotensin-converting enzyme inhibitors play an important role by reducing neurohormonal activation and improving cardiac function. Angiotensin receptor blockers may be used as alternatives in patients who cannot tolerate these medications. Angiotensin receptor-neprilysin inhibitors have emerged as one of the most effective treatment options for patients with heart failure and reduced ejection fraction. Beta-blockers are essential because they decrease sympathetic nervous system activity and improve ventricular performance. Mineralocorticoid receptor antagonists contribute to better outcomes by reducing fibrosis and fluid retention. Sodium-glucose cotransporter-2 inhibitors have recently become a major component of heart failure treatment due to their proven cardiovascular benefits. Clinical studies have demonstrated that these agents significantly reduce hospitalization and mortality rates. Diuretics remain important for controlling symptoms associated with fluid overload and congestion. Additional medications such as ivabradine may be considered in selected patients. Effective treatment requires careful dose adjustment and regular monitoring of therapeutic response. The integration of these modern pharmacological agents has substantially improved prognosis and quality of life for heart failure patients.

In addition to pharmacological therapy, device-based and interventional treatments play a crucial role in the management of heart failure, particularly in patients with advanced disease or persistent symptoms. These therapeutic approaches are designed to improve cardiac function, reduce complications, and enhance survival. One of the most important devices used in heart failure management is the implantable cardioverter-defibrillator. This device continuously monitors heart rhythm and delivers electrical shocks when life-threatening arrhythmias occur. Implantable cardioverter-defibrillators significantly reduce the risk of sudden cardiac death in high-risk patients. Another major advancement is cardiac resynchronization therapy, which improves the coordination of ventricular contractions through biventricular pacing. This therapy is especially beneficial for patients with reduced ejection fraction and electrical conduction abnormalities. Clinical studies have demonstrated improvements in cardiac performance, exercise capacity, and quality of life following cardiac resynchronization therapy. Catheter-based interventions have also gained importance in treating structural heart diseases associated with heart failure. Procedures such as transcatheter valve repair and replacement provide treatment options for patients who are unsuitable for conventional



**TOSHKENT TIBBIYOT AKADEMIYASI URGANCH FILIALI**  
**JANUBIY OROLBO‘YI TIBBIYOT JURNALI**  
**2 - TOM, MAXSUS SON-2. 2026**  
**14.00.00 - TIBBIYOT FANLARI ISSN: 3093-8740**

surgery. Advances in imaging technologies have further improved procedural accuracy and patient selection. These modern interventional strategies complement medical therapy and contribute to better long-term outcomes. The integration of device-based treatments into comprehensive heart failure management has transformed clinical practice and significantly improved patient prognosis.

Patients with advanced heart failure often require specialized therapeutic interventions when conventional medical treatment is no longer sufficient. Severe heart failure is associated with progressive symptoms, recurrent hospitalizations, and a high risk of mortality. In such cases, mechanical circulatory support devices may be utilized to maintain adequate blood flow and organ perfusion. Left ventricular assist devices are among the most commonly used support systems. These devices assist the failing heart by pumping blood from the left ventricle to the systemic circulation. Left ventricular assist devices can serve as a bridge to heart transplantation or as long-term therapy for patients who are not eligible for transplantation. Technological improvements have increased device durability and reduced complication rates. Heart transplantation remains the gold standard treatment for selected patients with end-stage heart failure. This procedure offers significant improvements in survival, functional capacity, and quality of life. However, the availability of donor organs remains a major limitation worldwide. Careful patient selection and comprehensive pre-transplant evaluation are essential for successful outcomes. Post-transplant management includes lifelong immunosuppressive therapy and regular medical follow-up. Ongoing advances in mechanical support systems and transplant medicine continue to improve the prognosis of patients with severe heart failure.

The future of heart failure management is focused on developing innovative therapies that target the underlying mechanisms of disease progression. Advances in molecular biology, genetics, and biomedical engineering have created new opportunities for personalized treatment strategies. Personalized medicine aims to tailor therapeutic interventions according to an individual patient's genetic profile, clinical characteristics, and risk factors. This approach may improve treatment effectiveness while minimizing adverse effects. Gene therapy has emerged as a promising area of research for correcting molecular abnormalities associated with heart failure. Scientists are investigating methods to enhance myocardial function through targeted genetic modifications. Stem cell therapy is another innovative strategy that seeks to regenerate damaged cardiac tissue and restore normal heart function. Although clinical results remain variable, ongoing studies continue to explore its therapeutic potential. Artificial intelligence and machine learning technologies are increasingly being incorporated into heart failure diagnosis and management. These technologies can assist healthcare professionals in risk prediction, treatment planning, and patient monitoring. Remote monitoring systems and wearable devices also enable early detection of clinical deterioration and support timely medical intervention. The integration of digital health technologies is expected to improve patient engagement and treatment adherence.

### **Results**

The results of this study indicate that modern treatment strategies have significantly improved the management of heart failure. Contemporary pharmacological therapies, particularly angiotensin receptor-neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors, were associated with reduced cardiovascular mortality and hospitalization rates. Patients receiving guideline-directed medical therapy demonstrated better symptom control, improved cardiac function, and enhanced quality of life compared with those receiving conventional treatment approaches. The findings also revealed that early diagnosis and timely initiation of therapy contributed to more favorable clinical outcomes and slowed disease progression.

Device-based interventions showed substantial benefits in selected patient populations. Implantable cardioverter-defibrillators effectively decreased the incidence of sudden cardiac death, while cardiac resynchronization therapy improved ventricular function and exercise capacity. In



**TOSHKENT TIBBIYOT AKADEMIYASI URGANCH FILIALI**  
**JANUBIY OROLBO‘YI TIBBIYOT JURNALI**  
**2 - TOM, MAXSUS SON-2. 2026**  
**14.00.00 - TIBBIYOT FANLARI ISSN: 3093-8740**

patients with advanced heart failure, mechanical circulatory support devices and heart transplantation provided significant improvements in survival and overall functional status. Furthermore, emerging technologies such as personalized medicine, artificial intelligence, gene therapy, and stem cell therapy demonstrated promising potential for future clinical application. Overall, the study findings confirm that the integration of modern pharmacological, interventional, and technological approaches has considerably enhanced the effectiveness of heart failure treatment.

### **Discussion**

The findings of this study are consistent with recent international research demonstrating that heart failure management has undergone substantial progress during the past decade. The introduction of novel pharmacological agents has transformed the treatment paradigm by targeting multiple pathophysiological pathways involved in disease progression. The observed reduction in mortality and hospitalization rates highlights the importance of evidence-based therapy and adherence to contemporary clinical guidelines. The effectiveness of device-based therapies further emphasizes the need for individualized treatment strategies. While pharmacological therapy remains the foundation of management, selected patients may achieve additional benefits through implantable cardiac devices and advanced interventional procedures. The results support the growing role of multidisciplinary care in optimizing treatment outcomes and improving long-term prognosis.

The increasing use of innovative technologies may further enhance the future management of heart failure. Personalized medicine and artificial intelligence have the potential to improve risk stratification, treatment selection, and patient monitoring. Although gene therapy and stem cell therapy remain largely experimental, ongoing clinical investigations suggest that these approaches may provide new opportunities for cardiac regeneration and functional recovery.

Despite significant therapeutic advances, heart failure continues to represent a major global health challenge. Many patients still experience disease progression, recurrent hospitalizations, and reduced quality of life. Therefore, continued research, early diagnosis, patient education, and the development of novel therapeutic approaches remain essential for improving clinical outcomes. The results of this study highlight the importance of integrating modern medical, technological, and interventional strategies to achieve optimal management of heart failure in contemporary clinical practice.

### **Conclusion**

Heart failure remains one of the most significant cardiovascular disorders worldwide and continues to be associated with high rates of morbidity, mortality, and healthcare utilization. The growing prevalence of risk factors such as hypertension, coronary artery disease, diabetes mellitus, obesity, and population aging has contributed to the increasing burden of this condition. Consequently, the development and implementation of effective treatment strategies have become a major priority in contemporary cardiovascular medicine. The findings of this study demonstrate that significant progress has been achieved in the management of heart failure through the introduction of modern pharmacological therapies and advanced technological interventions. Evidence-based medications, including angiotensin receptor-neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors, have substantially improved patient outcomes by reducing mortality, decreasing hospitalization rates, and enhancing quality of life. These therapeutic advances have transformed heart failure from a condition managed primarily through symptom control into a disease with increasingly effective long-term treatment options.

### **References**

1. Heidenreich P.A., Bozkurt B., Aguilar D. et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure // *Circulation*. – 2022. – Vol. 145, No. 18. – P. e895–e1032.
2. Anker S.D., Butler J., Filippatos G. et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction // *New England Journal of Medicine*. – 2021. – Vol. 385, No. 16. – P. 1451–1461.



**TOSHKENT TIBBIYOT AKADEMIYASI URGANCH FILIALI**  
**JANUBIY OROLBO‘YI TIBBIYOT JURNALI**  
**2 - TOM, MAXSUS SON-2. 2026**  
**14.00.00 - TIBBIYOT FANLARI ISSN: 3093-8740**

3. Packer M., Anker S.D., Butler J. et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure // *New England Journal of Medicine*. – 2020. – Vol. 383, No. 15. – P. 1413–1424.
4. Yancy C.W., Januzzi J.L., Allen L.A. et al. 2021 ACC Expert Consensus Decision Pathway on Heart Failure Treatment Optimization // *Journal of the American College of Cardiology*. – 2021. – Vol. 79, No. 17. – P. 1757–1780.
5. Beghini A., Rosano G.M.C., Metra M. 2024 Update in Heart Failure // *European Journal of Heart Failure*. – 2024. – Vol. 26, No. 1. – P. 8–25.
6. Hoevelmann J., Bauersachs J., Anker S.D. Update on Clinical Heart Failure Trials // *Clinical Research in Cardiology*. – 2025. – Vol. 114. – P. 1–15.
7. Kosiborod M.N., Butler J., et al. Semaglutide in Patients with Obesity-Related Heart Failure with Preserved Ejection Fraction // *The Lancet*. – 2024.
8. Ismoilova Y.A., Agababyan I.R., Akhatova V.P. Organization of Specialized Medical Care for Patients with Chronic Heart Failure // *Journal of Biomedicine and Practice*. – 2022. – No. 5. – P. 97–103.
9. Kityan S.A. Prevalence of Chronic Heart Failure in Andijan of the Republic of Uzbekistan // *World of Science*. – 2022. – Vol. 3, No. 11. – P. 1–6.
10. Abdullaev T.A., Tsoi I.A., Khudoyberganov O.K., Gulamov H.A. Innovative Approaches to Remote Monitoring in the Management of Chronic Heart Failure // *Cardiology of Uzbekistan*. – 2024. – Vol. 1, No. 3.

